ទំព័រដើម › មហារីកទ្រូង › ហ្ស៊ីយ៉ូហ្ស៊ីយ៉ា › Atlanta
ការសាកល្បងគ្លីនិកសម្រាប់ មហារីកទ្រូង នៅក្នុង Atlanta, GA
ការសិក្សាចំនួន 41 សម្រាប់ មហារីកទ្រូង កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Atlanta (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Atlanta Cancer Care - Northside Hospital, Atlanta
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Atlanta VA Medical Center, Decatur · ឆ្ងាយ 6 ម៉ាយ
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Winship Cancer Institute, Emory University, Atlanta
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
កំពុងជ្រើសរើសដំណាក់កាល 3
- Emory Proton Therapy Center, Atlanta
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
កំពុងជ្រើសរើសដំណាក់កាល 3
- Emory University Hospital, Atlanta
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
កំពុងជ្រើសរើសដំណាក់កាល 3
- Emory University Winship Cancer Institute, Atlanta
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
កំពុងជ្រើសរើសដំណាក់កាល 1
- Emory University School of Medicine - Winship Cancer Institute, Atlanta
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Winship Cancer Institute, Atlanta
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Winship Cancer Institute of Emory University, Atlanta
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
កំពុងជ្រើសរើសដំណាក់កាល 3
- Winship Cancer Institute, Atlanta
- Northside Hospital, Atlanta
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Emory University (Data Collection Only), Atlanta
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Winship Cancer Institute of Emory University, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Emory University, Atlanta
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
កំពុងជ្រើសរើសដំណាក់កាល 2
- Emory University, Atlanta
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
កំពុងជ្រើសរើសដំណាក់កាល 3
- Winship Cancer Institute of Emory University, Atlanta
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
កំពុងជ្រើសរើសដំណាក់កាល 3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Piedmont Hospital, Atlanta
- និង 5 ទៀត
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
កំពុងជ្រើសរើសដំណាក់កាល 1
- Emory University - Winship Cancer Institute, Atlanta
Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Emory University Hospital/Winship Cancer Institute, Atlanta
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Emory University, Atlanta
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
កំពុងជ្រើសរើសដំណាក់កាល 2
- Winship Cancer Institute at Emory University, Atlanta
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Northside Hospital, Atlanta
E-Mindfulness Approaches for Living After Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- និង 2 ទៀត
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Emory University, Atlanta
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Winship Cancer Institute, Emory University, Atlanta
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Winship Cancer Institute, Emory University, Atlanta
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
កំពុងជ្រើសរើសដំណាក់កាល 2
- GSK Investigational Site, Atlanta
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
កំពុងជ្រើសរើសដំណាក់កាល 3
- Emory University School of Medicine, Atlanta
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Emory University Hospital/Winship Cancer Institute, Atlanta
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Emory University/Winship Cancer Institute, Atlanta
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Winship Cancer Institute of Emory University, Atlanta
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
កំពុងជ្រើសរើសដំណាក់កាល 3
- Emory University Hospital Midtown, Atlanta
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
កំពុងជ្រើសរើសដំណាក់កាល 2
- Emory University Winship Cancer Institute, Atlanta
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Piedmont Hospital, Atlanta
- និង 5 ទៀត
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Research Site 111, Atlanta
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Emory Winship Cancer Institute, Atlanta
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Northside Hospital, Atlanta
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Emory University, Winship Cancer Institute, Atlanta
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- និង 1 ទៀត
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massive Bio SYNERGY-AI site, Atlanta
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
កំពុងជ្រើសរើសដំណាក់កាល 3
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Northside Hospital, Atlanta
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Piedmont Cancer Institute, Atlanta
- Emory University - Winship Cancer Institute, Atlanta
ការសាកល្បងសម្រាប់ មហារីកទ្រូង នៅក្នុងទីក្រុងផ្សេងទៀត
- New York City, NYការសិក្សា 136
- Houston, TXការសិក្សា 126
- Boston, MAការសិក្សា 112
- Nashville, TNការសិក្សា 81
- Los Angeles, CAការសិក្សា 73
- Edison, NJការសិក្សា 68
- St. Louis, MOការសិក្សា 64
- Queens, NYការសិក្សា 64
- Durham, NCការសិក្សា 64
- Chicago, ILការសិក្សា 59
- Philadelphia, PAការសិក្សា 56
- Dallas, TXការសិក្សា 55
ការសិក្សាផ្សេងទៀតនៅក្នុង Atlanta
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 49
- Non-Small Cell Lung Cancerការសិក្សា 47
- ជំងឺ Multiple Myelomaការសិក្សា 42
- មហារីកតូចការសិក្សា 33
- ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ការសិក្សា 31
- មហារីកស៊ុតការសិក្សា 29
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 29
- មហារីកសួតការសិក្សា 29
- មហារីកដែលរីករាលដាលការសិក្សា 28
- ជំងឺធ្លាក់ទឹកចិត្តធ្ងន់ធ្ងរការសិក្សា 25
- បេះដូងខ្សោយការសិក្សា 25
- មហារីកកោសិកាស្រអាប់នៅក្បាល និងបំបៅកការសិក្សា 24
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 6 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។